Gossamer Bio Inc

Gossamer Bio Inc. a clinical-stage biopharmaceutical company focuses on discovering acquiring developing and commercializing therapeutics in the disease areas of immunology inflammation and oncology in the United States. The company is developing GB002 an inhaled small molecule platelet-derived growth factor receptor or PDGFR colonystimulating factor 1 receptor or CSF1R and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004 a gut-targeted oral small molecule for the treatment of inflammatory bowel disease; GB5121 an oral irreversible covalent small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208 an oral small molecule BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG Bio Inc. and changed its name to Gossamer Bio Inc. in 2017. Gossamer Bio Inc. was incorporated in 2015 and is headquartered in San Diego California.